Published in Transl Psychiatry on November 20, 2012
Schizophrenia. Lancet (2016) 1.83
Advancing understanding of executive function impairments and psychopathology: bridging the gap between clinical and cognitive approaches. Front Psychol (2015) 1.33
Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis: do the cognitive deficits progress over, or after, the onset of psychosis? Schizophr Bull (2013) 1.10
Patterns of Gray Matter Abnormalities in Schizophrenia Based on an International Mega-analysis. Schizophr Bull (2014) 1.08
Detecting the psychosis prodrome across high-risk populations using neuroanatomical biomarkers. Schizophr Bull (2014) 0.97
A Unified Framework for Brain Segmentation in MR Images. Comput Math Methods Med (2015) 0.97
The neurobiology and treatment of first-episode schizophrenia. Mol Psychiatry (2014) 0.93
Brain structural changes in schizoaffective disorder compared to schizophrenia and bipolar disorder. Acta Psychiatr Scand (2015) 0.92
Deficits in predictive coding underlie hallucinations in schizophrenia. J Neurosci (2014) 0.90
Duration of untreated psychosis is associated with temporal and occipitotemporal gray matter volume decrease in treatment naïve schizophrenia. PLoS One (2013) 0.89
Common mechanisms of excitatory and inhibitory imbalance in schizophrenia and autism spectrum disorders. Curr Mol Med (2015) 0.89
Cannabis-related episodic memory deficits and hippocampal morphological differences in healthy individuals and schizophrenia subjects. Hippocampus (2015) 0.85
Role of perinatal long-chain omega-3 fatty acids in cortical circuit maturation: Mechanisms and implications for psychopathology. World J Psychiatry (2015) 0.85
Diffusion tensor imaging study of the fornix in first episode schizophrenia and in healthy controls. Schizophr Res (2014) 0.84
Glutamate-mediated excitotoxicity in schizophrenia: a review. Eur Neuropsychopharmacol (2014) 0.84
Temporal and spatial evolution of grey matter atrophy in primary progressive multiple sclerosis. Neuroimage (2013) 0.82
Approaching a network connectivity-driven classification of the psychosis continuum: a selective review and suggestions for future research. Front Hum Neurosci (2015) 0.82
Altered cortical thickness related to clinical severity but not the untreated disease duration in schizophrenia. Schizophr Bull (2013) 0.82
In vivo imaging of brain microglial activity in antipsychotic-free and medicated schizophrenia: a [(11)C](R)-PK11195 positron emission tomography study. Mol Psychiatry (2016) 0.81
Connectome-wide network analysis of youth with Psychosis-Spectrum symptoms. Mol Psychiatry (2015) 0.81
An fMRI study of multimodal selective attention in schizophrenia. Br J Psychiatry (2015) 0.80
Association of serum VEGF levels with prefrontal cortex volume in schizophrenia. Mol Psychiatry (2015) 0.80
A longitudinal study of alterations of hippocampal volumes and serum BDNF levels in association to atypical antipsychotics in a sample of first-episode patients with schizophrenia. PLoS One (2014) 0.80
Fornix as an imaging marker for episodic memory deficits in healthy aging and in various neurological disorders. Front Aging Neurosci (2015) 0.80
Investigation of Heschl's gyrus and planum temporale in patients with schizophrenia and bipolar disorder: a proton magnetic resonance spectroscopy study. Schizophr Res (2014) 0.79
DUF1220 copy number is associated with schizophrenia risk and severity: implications for understanding autism and schizophrenia as related diseases. Transl Psychiatry (2015) 0.79
Polymorphisms in MIR137HG and microRNA-137-regulated genes influence gray matter structure in schizophrenia. Transl Psychiatry (2016) 0.78
Corpus callosum size and diffusion tensor anisotropy in adolescents and adults with schizophrenia. Psychiatry Res (2015) 0.78
Association of white matter deficits with clinical symptoms in antipsychotic-naive first-episode schizophrenia: an optimized VBM study using 3T. MAGMA (2013) 0.78
Extensive gray matter volume reduction in treatment-resistant schizophrenia. Int J Neuropsychopharmacol (2015) 0.77
Similar age-related decline in cortical activity over frontotemporal regions in schizophrenia: a multichannel near-infrared spectroscopy study. Schizophr Bull (2014) 0.76
Altered resting-state EEG source functional connectivity in schizophrenia: the effect of illness duration. Front Hum Neurosci (2015) 0.76
Progressive reduction of visual P300 amplitude in patients with first-episode schizophrenia: an ERP study. Schizophr Bull (2014) 0.76
Longitudinal regional brain volume loss in schizophrenia: Relationship to antipsychotic medication and change in social function. Schizophr Res (2015) 0.76
Brain oscillations in bipolar disorder and lithium-induced changes. Neuropsychiatr Dis Treat (2016) 0.76
Patterns of regional gray matter loss at different stages of schizophrenia: A multisite, cross-sectional VBM study in first-episode and chronic illness. Neuroimage Clin (2016) 0.75
Hemodynamic response function abnormalities in schizophrenia during a multisensory detection task. Hum Brain Mapp (2015) 0.75
Altered regional brain function in the treatment-naive patients with somatic symptom disorder: a resting-state fMRI study. Brain Behav (2016) 0.75
Brain-Derived Neurotrophic Factor and Suicide in Schizophrenia: Critical Role of Neuroprotective Mechanisms as an Emerging Hypothesis. Indian J Psychol Med (2016) 0.75
Volumetric, relaxometric and diffusometric correlates of psychotic experiences in a non-clinical sample of young adults. Neuroimage Clin (2016) 0.75
Structural brain changes are associated with response of negative symptoms to prefrontal repetitive transcranial magnetic stimulation in patients with schizophrenia. Mol Psychiatry (2016) 0.75
Neuroimaging Biomarkers for Psychosis. Curr Behav Neurosci Rep (2015) 0.75
Impaired Tuning of Neural Ensembles and the Pathophysiology of Schizophrenia: A Translational and Computational Neuroscience Perspective. Biol Psychiatry (2017) 0.75
Discriminative analysis of schizophrenia using support vector machine and recursive feature elimination on structural MRI images. Medicine (Baltimore) (2016) 0.75
Amygdala volume is reduced in early course schizophrenia. Psychiatry Res (2016) 0.75
Global brain asymmetry is increased in schizophrenia and related to avolition. Acta Psychiatr Scand (2017) 0.75
Deep Independence Network Analysis of Structural Brain Imaging: Application to Schizophrenia. IEEE Trans Med Imaging (2016) 0.75
Gray matter volume alterations in first-episode drug-naïve patients with deficit and nondeficit schizophrenia. Psychiatry Res (2015) 0.75
Neuropsychological and cerebral morphometric aspects of negative symptoms in schizophrenia: negative symptomatology is associated with specific mnestic deficits in schizophrenic patients. BMC Psychiatry (2014) 0.75
Sleep and Psychiatric Disorders in Persons With Mild Traumatic Brain Injury. Curr Psychiatry Rep (2017) 0.75
Post-mortem molecular profiling of three psychiatric disorders. Genome Med (2017) 0.75
The effect of duration of illness and antipsychotics on subcortical volumes in schizophrenia: Analysis of 778 subjects. Neuroimage Clin (2017) 0.75
Measuring inconsistency in meta-analyses. BMJ (2003) 128.20
Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 122.24
Voxel-based morphometry--the methods. Neuroimage (2000) 34.79
Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry (2000) 4.84
Abnormalities of the left temporal lobe and thought disorder in schizophrenia. A quantitative magnetic resonance imaging study. N Engl J Med (1992) 4.54
Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. Am J Psychiatry (2005) 4.31
Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry (2005) 3.78
Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry (2011) 3.53
Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychol Med (2009) 3.34
Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol (2006) 3.30
Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: a meta-analytic study. Arch Gen Psychiatry (1998) 2.92
Meta-analysis of gray matter anomalies in schizophrenia: application of anatomic likelihood estimation and network analysis. Biol Psychiatry (2008) 2.91
Handedness, language lateralisation and anatomical asymmetry in schizophrenia: meta-analysis. Br J Psychiatry (2001) 2.74
Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain? Arch Gen Psychiatry (2002) 2.48
Auditory hallucinations and smaller superior temporal gyral volume in schizophrenia. Am J Psychiatry (1990) 2.41
Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry (2003) 2.39
Dysregulation of working memory and default-mode networks in schizophrenia using independent component analysis, an fBIRN and MCIC study. Hum Brain Mapp (2009) 2.28
Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophr Bull (2005) 2.13
Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. Arch Gen Psychiatry (2007) 2.13
Unreality symptoms and volumetric measures of Heschl's gyrus and planum temporal in first-episode psychosis. Biol Psychiatry (2005) 2.11
The planum temporale: a systematic, quantitative review of its structural, functional and clinical significance. Brain Res Brain Res Rev (1999) 2.10
Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am J Psychiatry (1998) 2.09
Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Arch Gen Psychiatry (2001) 2.02
Lower left temporal lobe MRI volumes in patients with first-episode schizophrenia compared with psychotic patients with first-episode affective disorder and normal subjects. Am J Psychiatry (1998) 2.00
Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology (2007) 1.98
Progressive decrease of left Heschl gyrus and planum temporale gray matter volume in first-episode schizophrenia: a longitudinal magnetic resonance imaging study. Arch Gen Psychiatry (2003) 1.94
Longitudinal study of brain morphology in first episode schizophrenia. Biol Psychiatry (2001) 1.86
Association of cerebral deficits with clinical symptoms in antipsychotic-naive first-episode schizophrenia: an optimized voxel-based morphometry and resting state functional connectivity study. Am J Psychiatry (2008) 1.86
Brain morphology in first-episode schizophrenia: a meta-analysis of quantitative magnetic resonance imaging studies. Schizophr Res (2005) 1.84
A prospective longitudinal volumetric MRI study of superior temporal gyrus gray matter and amygdala-hippocampal complex in chronic schizophrenia. Schizophr Res (2009) 1.82
What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr Bull (2008) 1.80
Progressive cortical change during adolescence in childhood-onset schizophrenia. A longitudinal magnetic resonance imaging study. Arch Gen Psychiatry (1999) 1.78
Gender differences in young adults with first-episode schizophrenia spectrum disorders at baseline in the Danish OPUS study. J Nerv Ment Dis (2007) 1.75
Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. Biol Psychiatry (2011) 1.75
Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatry (1994) 1.72
Ventricular enlargement in poor-outcome schizophrenia. Biol Psychiatry (1998) 1.70
Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Arch Gen Psychiatry (2002) 1.68
Neuroanatomy of vulnerability to psychosis: a voxel-based meta-analysis. Neurosci Biobehav Rev (2010) 1.66
Progressive lateral ventricular enlargement in schizophrenia: a meta-analysis of longitudinal MRI studies. Schizophr Res (2010) 1.64
Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biol Psychiatry (2007) 1.58
Progressive brain change in schizophrenia: a prospective longitudinal study of first-episode schizophrenia. Biol Psychiatry (2011) 1.56
Brain anatomical abnormalities in high-risk individuals, first-episode, and chronic schizophrenia: an activation likelihood estimation meta-analysis of illness progression. Schizophr Bull (2009) 1.51
Progressive brain volume loss during adolescence in childhood-onset schizophrenia. Am J Psychiatry (2003) 1.46
Meta-analysis of brain and cranial size in schizophrenia. Schizophr Res (1996) 1.45
Neocortical gray matter volume in first-episode schizophrenia and first-episode affective psychosis: a cross-sectional and longitudinal MRI study. Biol Psychiatry (2007) 1.40
Superior temporal gyrus and the course of early schizophrenia: progressive, static, or reversible? J Psychiatr Res (1998) 1.39
Anatomical abnormalities of the anterior cingulate cortex in schizophrenia: bridging the gap between neuroimaging and neuropathology. Schizophr Bull (2008) 1.37
The 'big bang' theory of the origin of psychosis and the faculty of language. Schizophr Res (2008) 1.36
Volumetric white matter abnormalities in first-episode schizophrenia: a longitudinal, tensor-based morphometry study. Am J Psychiatry (2007) 1.33
Association between smaller left posterior superior temporal gyrus volume on magnetic resonance imaging and smaller left temporal P300 amplitude in first-episode schizophrenia. Arch Gen Psychiatry (2002) 1.33
Progressive changes in the development toward schizophrenia: studies in subjects at increased symptomatic risk. Schizophr Bull (2008) 1.32
Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study. Neuropsychopharmacology (2005) 1.32
The timing of brain morphological changes in schizophrenia and their relationship to clinical outcome. Biol Psychiatry (1992) 1.31
The functional neuroanatomy of symptom dimensions in schizophrenia: a qualitative and quantitative review of a persistent question. Neurosci Biobehav Rev (2009) 1.30
Volume changes in gray matter in patients with schizophrenia. Am J Psychiatry (2002) 1.27
Mapping gray matter development: implications for typical development and vulnerability to psychopathology. Brain Cogn (2009) 1.24
Differences and similarities in insular and temporal pole MRI gray matter volume abnormalities in first-episode schizophrenia and affective psychosis. Arch Gen Psychiatry (2003) 1.22
Superior temporal gyrus in schizophrenia: a volumetric magnetic resonance imaging study. Schizophr Res (2000) 1.19
Neuroimaging and emerging psychotic disorders: the Melbourne ultra-high risk studies. Int Rev Psychiatry (2007) 1.18
Cerebral ventricular change over the first 10 years after the onset of schizophrenia. Psychiatry Res (2004) 1.17
Schizophrenia--a brain disease? A critical review of structural and functional cerebral abnormality in the disorder. Br J Psychiatry (1995) 1.13
N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology (Berl) (2005) 1.11
Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia. Schizophr Res (2005) 1.09
Posterior superior temporal gyrus in schizophrenia: grey matter changes and clinical correlates. Schizophr Res (1995) 1.07
Progressive reduction of temporal lobe structures in childhood-onset schizophrenia. Am J Psychiatry (1998) 1.06
Anomalous cerebral asymmetry and language processing in schizophrenia. Schizophr Bull (1997) 1.06
Symptom dimensions and brain morphology in schizophrenia and related psychotic disorders. J Psychiatr Res (1996) 1.02
Superior temporal gyral volumes and laterality correlates of auditory hallucinations in schizophrenia. Biol Psychiatry (1999) 1.02
Progressive brain changes in children and adolescents with first-episode psychosis. Arch Gen Psychiatry (2012) 1.02
Clozapine but not haloperidol Re-establishes normal task-activated rCBF patterns in schizophrenia within the anterior cingulate cortex. Neuropsychopharmacology (2004) 1.01
Volumes of ventricular system subdivisions measured from magnetic resonance images in first-episode schizophrenic patients. Arch Gen Psychiatry (1992) 1.00
Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus. Neuropsychopharmacology (2004) 0.99
Focus on geriatric psychiatry: schizophrenia in later life: clinical symptoms and social well-being. Psychiatr Serv (2008) 0.98
Effect of antipsychotics on regional cerebral blood flow measured with positron emission tomography. Neuropsychopharmacology (1997) 0.96
Brain structural changes associated with chronicity and antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol (2009) 0.95
The effects of antipsychotic treatment on cerebral structure and function in schizophrenia. Int Rev Psychiatry (2007) 0.95
Hippocampal volume change in schizophrenia. J Clin Psychiatry (2010) 0.95
Normal asymmetry of the planum temporale in patients with schizophrenia. Three-dimensional cortical morphometry with MRI. Br J Psychiatry (1995) 0.93
Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia. Brain Res (1998) 0.93
In vivo morphometry of planum temporale asymmetry in first-episode schizophrenia. Schizophr Res (1994) 0.92
Language and thought disorder in schizophrenia: brain morphological correlates. Schizophr Res (1995) 0.92
Ten year progressive ventricular enlargement in schizophrenia: an MRI morphometrical study. Psychiatry Clin Neurosci (2001) 0.91
Reduced frontal and occipital lobe asymmetry on the CT-scans of schizophrenic patients. Its specificity and clinical significance. J Neural Transm Gen Sect (1995) 0.90
Schizophrenia as a progressive brain disease. Eur Psychiatry (2008) 0.90
Progression of brain volume changes in adolescent-onset psychosis. Schizophr Bull (2008) 0.90
Neuroanatomical markers of genetic liability to psychosis and first episode psychosis: a voxelwise meta-analytical comparison. World J Biol Psychiatry (2012) 0.90
Brain volume changes after withdrawal of atypical antipsychotics in patients with first-episode schizophrenia. J Clin Psychopharmacol (2011) 0.89
Uniting Kraepelin and Bleuler: the psychology of schizophrenia and the biology of temporal lobe abnormalities. Harv Rev Psychiatry (1997) 0.87
A follow-up MRI study of the superior temporal subregions in schizotypal disorder and first-episode schizophrenia. Schizophr Res (2010) 0.87
Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brain. Eur Neuropsychopharmacol (2005) 0.87
Tardive dyskinesia and substrates of energy metabolism in CSF. Am J Psychiatry (1995) 0.86
Subcortical and cortical gray matter differences between Kraepelinian and non-Kraepelinian schizophrenia patients identified using voxel-based morphometry. Psychiatry Res (2010) 0.85
Induction of NF-kappaB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: suppression of NF-kappaB and neuroprotection by antioxidants. J Neurosci (1998) 0.85
Paracingulate sulcus asymmetry; sex difference, correlation with semantic fluency and change over time in adolescent onset psychosis. Psychiatry Res (2010) 0.84
An MRI study of the superior temporal subregions in first-episode patients with various psychotic disorders. Schizophr Res (2009) 0.84
Neurobiology and phenotypic expression in early onset schizophrenia. Early Interv Psychiatry (2011) 0.83
Reduced planum temporale volume and delusional behaviour in patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci (2007) 0.83
Reduced language lateralization in first-episode medication-naive schizophrenia. Schizophr Res (2011) 0.83
Lack of progression of brain abnormalities in first-episode psychosis: a longitudinal magnetic resonance imaging study. Psychol Med (2010) 0.83
Cerebral ventricular enlargement in schizophreniform disorder does not progress. A seven year follow-up study. Schizophr Res (1994) 0.82
Brain morphology in first-episode schizophrenia: a meta-analysis of quantitative magnetic resonance imaging studies. Schizophr Res (2005) 1.84
Neuroanatomy of vulnerability to psychosis: a voxel-based meta-analysis. Neurosci Biobehav Rev (2010) 1.66
Are SSRI antidepressants a clinically homogeneous class of compounds? Lancet (1994) 1.40
Direct transition to long-acting risperidone--analysis of long-term efficacy. J Psychopharmacol (2005) 0.97
In vivo serotonin 5HT(2A) receptor binding and personality traits in healthy subjects: a positron emission tomography study. Neuroimage (2002) 0.96
Depressive disorders and personality variables in HIV positive and negative intravenous drug-users. J Affect Disord (2001) 0.84
Patterns of brain structural changes in first-contact, antipsychotic drug-naive patients with schizophrenia. AJNR Am J Neuroradiol (2013) 0.84
Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months. Int J Clin Pharmacol Ther (2008) 0.84
Brain morphology in schizophrenia: a 2- to 5-year CT scan follow-up study. Acta Psychiatr Scand (1988) 0.84
Timing of stroke in elderly people exposed to typical and atypical antipsychotics: a replication cohort study after the paper of Kleijer, et al. J Psychopharmacol (2009) 0.83
Long-acting risperidone improves negative symptoms in stable psychotic patients. J Psychopharmacol (2008) 0.82
Cytokine profiles in drug-naive schizophrenic patients. Schizophr Res (2001) 0.81
MHPG, amitriptyline and affective disorders. A longitudinal study. Int Pharmacopsychiatry (1976) 0.80
The HLA system and the clinical response to treatment with chlorpromazine. Br J Psychiatry (1976) 0.79
Cortical atrophy in schizophrenia. Prevalence and associated features. Schizophr Res (1991) 0.79
Alpha reactivity in schizophrenia and in schizophrenic spectrum disorders: demographic, clinical and hemispheric assessment. Int J Psychophysiol (1989) 0.79
Pituitary-gonadal function in heroin addicts. Neuropsychobiology (1977) 0.79
Celibacy and fertility rates in patients with major affective disorders: the relevance of delusional symptoms and suicidal behaviour. Acta Psychiatr Scand (1990) 0.78
Psychopathologic, neuropsychological and functional outcome measures during cognitive rehabilitation in schizophrenia: a prospective controlled study in a real-world setting. Eur Psychiatry (2010) 0.78
Combined measure of smooth pursuit eye movements and ventricle-brain ratio in schizophrenic disorders. Psychiatry Res (1987) 0.76
Early life events and affective disorder revisited. Br J Psychiatry (1986) 0.76
Plasma and intracellular kinetics of lithium after oral administration of various lithium salts. Eur J Clin Pharmacol (1977) 0.76
Developmental brain abnormalities in schizophrenia: contributions of genetic and perinatal factors. Arch Gen Psychiatry (1995) 0.76
Reducing the "revolving door" phenomenon. Am J Psychiatry (1996) 0.76
EEG power spectrum profile and structural CNS characteristics in schizophrenia. Biol Psychiatry (1990) 0.76
CT scan abnormalities and outcome of chronic schizophrenia. Am J Psychiatry (1991) 0.75
Risk factors in schizophrenia. Br J Psychiatry (1989) 0.75
beta-Endorphin and beta-lipotropin plasma levels in chronic schizophrenia, primary affective disorders and secondary affective disorders. Psychoneuroendocrinology (1981) 0.75
Life events and headache. Cephalalgia (1985) 0.75
Deranged anterior pituitary responsiveness to hypothalamic hormones in depressed patients. Arch Gen Psychiatry (1978) 0.75
Psychotropic drugs and their relationship with psychopathology of affective disorders. Prog Neuropsychopharmacol (1979) 0.75
[Massive intracranial calcifications in a newborn infant with cytomegalic disease]. Minerva Pediatr (1976) 0.75
Heterogeneity of major affective disorders. Biological and clinical evidence. Encephale (1985) 0.75
Platelet alpha 2-adrenoceptors in major depression: relationship with urinary 4-hydroxy-3-methoxyphenylglycol and age at onset. J Psychiatr Res (1985) 0.75
Neuroendocrine abnormalities in depressive illness. Adv Biochem Psychopharmacol (1982) 0.75
Interference of sulpiride with the mitogenic activation of lymphocytes cultured in vitro. Arzneimittelforschung (1976) 0.75
HLA typing and affective disorders: a study in the Italian population. Neuropsychobiology (1978) 0.75
Further study on N1-methylnicotinamide urinary output in patients with affective disorders. Agressologie (1977) 0.75
Variables associated with the hospitalization of psychiatric emergencies evaluated in the community. Eur Psychiatry (1999) 0.75
N-methylnicotinamide excretion and affective disorders. Psychol Med (1976) 0.75
Interepisode reliability of urinary MHPG excretion in major depression. Biol Psychiatry (1988) 0.75
N1-Methylnicotinamide urinary output in multiple sclerosis affected patients. Acta Vitaminol Enzymol (1975) 0.75
Noxiptylin and masked depression. Agressologie (1978) 0.75
Erythrocyte/plasma lithium ratios. Lancet (1977) 0.75
Renal function in chronic lithium-treated patients. Acta Psychiatr Scand (1989) 0.75
3-Methoxy-4-hydroxyphenylglycol and primary depression: clinical and pharmacological considerations. Biol Psychiatry (1979) 0.75
Histocompatibility antigens and effects of neuroactive drugs on phytohaemagglutinin stimulation of lymphocytes in vitro. Arzneimittelforschung (1977) 0.75
Is urinary MHPG a real predictor of drug response in primary depression? Adv Biochem Psychopharmacol (1982) 0.75
Brain morphology in schizophrenic disorder: prevalence and correlates of diffuse (cortical and subcortical) brain atrophy. Psychiatry Res (1989) 0.75
Dantrolene in lethal catatonia. Am J Psychiatry (1991) 0.75
Interference between anti-HLA antibodies and adrenergic receptor-binding drugs. Tissue Antigens (1977) 0.75
HLA-SD antigens and schizophrenia: statistical and genetical considerations. Tissue Antigens (1976) 0.75
Serum creatine kinase in acute psychosis. Br J Psychiatry (1976) 0.75
[Some hematochemical changes during acupuncture. Preliminary report]. Minerva Med (1976) 0.75